first vaccination – Page 7 – Communicable Diseases Research

Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine

Immunology

Published on 2022-01-312022-11-01
Journal: Frontiers in Immunology [Category] COVID-19,

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients A multicenter prospective observational study

혈액 투석 환자에서 동종 BNT/BNT 및 ChAd/ChAd SARS-CoV-2 백신 접종과 비교한 이종 ChAd/BNT의 체액 면역원성 및 내약성 다기관 전향적 관찰 연구

Observational Study

Published on 2022-01-272022-09-10
Journal: Journal of Nephrology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법,

[키워드] Abstract Adverse reaction Adverse reactions antibody appear AstraZeneca BNT BNT162b2 BNT162b2 vaccine ChAd ChAdOx1 ChAdOx1-nCoV-19 COVID-19 dose first dose first vaccination Hemodialysis Heterologous homologous Humoral immunity humoral immunogenicity IgG antibody IgG level IgG levels induce kidney limitation median mRNA-/vectored vaccines multicenter multivariable Multivariable regression analysis nCoV nucleocapsid observational study Patient patients percentile prospective observational study regression analysis Result SARS-CoV-2 SARS-CoV-2 spike IgG SARS-CoV-2 vaccination second dose severe adverse reactions Side effect Side effects significantly higher Tolerability vaccination Vaccine were assessed
[DOI] 10.1007/s40620-022-01247-7 PMC 바로가기 [Article Type] Observational Study

Vaccine-induced COVID-19 mimicry syndrome

백신 유발 코로나19 모방 증후군

Research Article

Published on 2022-01-272022-09-10
Journal: eLife [Category] 변종, 유전자 메커니즘,

[키워드] accompanied ACE2 receptor adenoviral vector Adenoviral vector-based vaccine adenoviral vector-based vaccines Avoiding binding caused Cell cells COVID-19 COVID-19 pandemic event explain first vaccination full-length Human immune immunization in some mechanism mRNA mRNA coding mRNA-based vaccines occurred Protein reported RNA RNA virus SARS-CoV-2 SARS-CoV-2 spike protein secreted Side effect spike Spike protein splice variants splicing syndrome the SARS-CoV-2 thrombocytopenia thromboembolic Thromboembolic event Thromboembolic events thrombosis thrombotic Thrombotic thrombocytopenia transmembrane vaccination Vaccine design Vaccines variant venous venous sinus
[DOI] 10.7554/eLife.74974 PMC 바로가기 [Article Type] Research Article

Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination

Immunology

Published on 2022-01-252022-11-01
Journal: Frontiers in Immunology [Category] COVID-19,

[키워드] Activation adaptive adenoviral vector vaccine adenovirus vector vaccine age antibody Antibody titer association AZD1222 B cell CD14 CD27 CD3 CD56 CD86 Cell ChAdOx1 nCoV-19 collected connection correlated CpG Critical cytokine production double-negative B cell enrolled Ex vivo expression first vaccination FIVE flow cytometry granzyme B IFN-γ IGD imiquimod Immune cell immune response Immunity immunosenescence information Innate innate immune innate immune activation innate immune response Innate immunity LPS marker memory B cell monocyte naïve naïve B cell natural killer neutralization Neutralizing antibodies neutralizing antibody NK cell Older pattern recognition receptor Production response responses Result SARS-CoV-2 vaccines SARS-CoV2 serum significantly higher stimulated subject sVNT TLR TLR agonist TLR stimulation TLR9 Toll-like receptor vaccination vaccinee Virus neutralization were measured
[DOI] 10.3389/fimmu.2022.807454 PMC 바로가기 [Article Type] Immunology

Humoral immune response after different SARS-CoV-2 vaccination regimens

상이한 SARS-COV-2 백신 접종 요법 후 체액 면역 반응

Research Article

Published on 2022-01-212022-09-01
Journal: BMC Medicine [Category] SARS, 변종, 진단, 치료기술,

[키워드] age Alpha anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antibody Response Antigen AstraZeneca avidity AZD1222 B.1.1.7 B.1.1.7 variant B.1.617.2 binding BNT162b2 boost booster vaccination ChAdOx1 ChAdOx1 nCoV-19 comparable Concentration correlation COVID-19 cVNT delta variant examined first vaccination followed by Heterologous homologous humoral immune response Humoral immunity IgG IgG antibodies IgG antibody immune response immunoblot Immunoglobulin Immunoglobulin G individual investigation leads Maturity process Moderna mRNA mRNA vaccine neutralisation test Neutralising Antibodies Occurrence Pfizer/BioNTech Prevalence RBD Receptor binding domain recipient reduction in regimen Result robust S-protein SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 vaccination sera Seroconversion significantly higher significantly lower strength subunit supplementary material sVNT tested the antibody response the RBD the SARS-CoV-2 the vaccine titre titres trimeric vaccination Vaccination schemes Vaccine vaccine dose vaccinee variant Virus neutralisation Virus variants of concern VoC was done was measured was used were measured
[DOI] 10.1186/s12916-021-02231-x PMC 바로가기 [Article Type] Research Article

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial

COVID-19 백신 접종에서 Elecsys Anti-SARS-CoV-2 S 어세이의 임상적 유용성: mRNA-1273 1상 시험의 탐색적 분석

Clinical Trial

Published on 2022-01-192022-09-11
Journal: Frontiers in Immunology [Category] 임상, 치료기술,

[키워드] 2019-nCoV absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-SARS-CoV-2 S antibody antibody levels automated baseline choice clinical clinical utility collected coronavirus correlated correlation COVID-19 Day detectable dose Elecsy ELISA ELISAs first vaccination geometric mean geometric mean concentration healthy heterogeneous humoral immune response increases in injection International international standard mRNA mRNA-1273 nanoluciferase neutralization test neutralization tests Neutralizing antibodies participant Participants Phase 1 phase 1 trial Protein pseudovirus neutralizing antibody pseudovirus neutralizing antibody assay quantification Quantitative quantitative serology RBD RBD ELISA RBD-specific antibodies RBD-specific antibody Receptor binding domain respiratory Result Roche S-2P Sample SARS-CoV-2 second vaccination Seroconversion seroconverted severe acute respiratory syndrome Coronavirus shown specific antibodies specificity Spike protein the Spike U/mL vaccination Vaccine vaccine-induced antibody response WHO
[DOI] 10.3389/fimmu.2021.798117 PMC 바로가기 [Article Type] Clinical Trial

Multiple evanescent white dot syndrome following vaccination for COVID-19 A case report

4900

Published on 2022-01-142022-10-30
Journal: Medicine [Category] COVID-19,

Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations

Article

Published on 2022-01-012022-10-06
Journal: JAMA Oncology [Category] Fulltext, SARS, 진단, 치료기술, 치료제,

[키워드] age anti-S anti-S antibody anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibody antibody level Cancer Chemotherapy cohort study cohorts cohorts of patient collected Combination Community control group determine develop disease dose first vaccination HCW HCWs Health care worker hematological highest hospital immunization immunocompromised individuals Immunotherapy independent Infection knowledge Lower lowest malignant tumor median men nucleocapsid outcome Patient Patients with cancer Protein Received response retrospective cohort study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination Seroconversion serum sample solid tumor subgroup suggested therapy Total treated Treatment vaccination were measured women worker
[DOI] 10.1001/jamaoncol.2021.5437 PMC 바로가기 [Article Type] Article

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?

ocrelizumab 치료 MS 환자에서 SARS-CoV-2 백신 접종 후 세로 체액 반응: 기다렸다가 다시 채우려면?

Article

Published on 2022-01-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, 치료기술,

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine

BBIBP-CorV(Sinopharm) 비활성화 바이러스 백신 접종 후 질병 조절 요법을 받는 다발성 경화증 환자의 SARS-CoV-2 혈청학: 같은 이야기, 다른 백신

Article

Published on 2022-01-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] SARS, 치료기술,

[키워드] Analysis anti-CD20 therapy anti-SARS-CoV-2 association BBIBP-CorV booster carried Cohort cohort study cohorts contribute COVID-19 COVID-19 vaccines detect Disease-modifying therapies dose Efficiency Evidence fingolimod first vaccination healthy humoral Humoral response humoral responses IgG inactivated indicated investigated Iran less Linear regression mode mRNA Multiple multiple sclerosis multivariable analysis multivariable logistic regression multivariable logistic regression model participant Participants phlebotomy Previous studies previous study receive receptor SARS-CoV-2 seroconverted serology serology testing serostatus Sinopharm sphingosine spike Statistical power Statistical tests t-test therapy vaccination Vaccination strategies Vaccination strategy Vaccine vaccine dose Viral vector Viral vector vaccine Viral vector vaccines virus was used
[DOI] 10.1016/j.msard.2021.103417 PMC 바로가기 [Article Type] Article